TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Sells $34,172.46 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Richard Marshak sold 6,597 shares of the firm’s stock in a transaction on Monday, May 19th. The stock was sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the transaction, the insider now directly owns 69,101 shares of the company’s stock, valued at approximately $357,943.18. This trade represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

TriSalus Life Sciences Stock Up 3.9%

Shares of TLSI stock opened at $5.56 on Friday. TriSalus Life Sciences, Inc. has a 12-month low of $3.50 and a 12-month high of $9.00. The company has a market capitalization of $179.43 million, a P/E ratio of -2.23 and a beta of 0.50. The firm has a 50-day moving average price of $5.42 and a 200 day moving average price of $5.04.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the prior year, the firm earned ($0.60) earnings per share. As a group, research analysts expect that TriSalus Life Sciences, Inc. will post -1.55 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on TLSI shares. Roth Mkm reiterated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Lake Street Capital began coverage on shares of TriSalus Life Sciences in a research report on Thursday, February 13th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, March 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, TriSalus Life Sciences presently has a consensus rating of “Buy” and an average target price of $10.93.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new stake in shares of TriSalus Life Sciences during the first quarter worth $187,000. Charles Schwab Investment Management Inc. bought a new stake in shares of TriSalus Life Sciences during the first quarter worth $55,000. Connective Capital Management LLC acquired a new stake in TriSalus Life Sciences in the 4th quarter valued at about $140,000. Bridgeway Capital Management LLC increased its position in TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock valued at $326,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Bank of America Corp DE increased its position in TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock valued at $894,000 after acquiring an additional 178,298 shares in the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.